Lawyer for Aviator LLC Details Origin of Aviator Logo Following Court Victory
After winning an important $330 million infringement ruling by the Georgian Court of First Instance against Adjarabet and Spribe OÜ, and in response to statements published in the media by the defendants, Nikoloz Gogilidze, Managing Partner of the law firm Mikadze Gegetchkori Taktakishvili LLC which represents Aviator LLC, says that the Aviator brand (the name and the logo) was created in 2016-2017 by Georgian businessman Teimuraz Ugulava.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904224604/en/
Left image: Original logo owned by Aviator LLC, used illegally in Georgia by Adjarabet and Spribe OÜ until January 2024. Right image: Modified logo used internationally by Spribe OÜ, invalidated by Aviator LLC in Georgia. (Graphic: Business Wire)
Mr. Gogilidze shares further history of the ownership of the brand, as detailed in submissions before the court:
In 2018, the “Aviator” trademark was duly registered with the Georgian State Trademark Agency (Sakpatenti; www.sakpatenti.gov.ge/en) by City Loft LLC, company solely owned by Teimuraz Ugulava. In 2018, Mr. Ugulava owned two gambling companies, the land casino Aviator and the online platform Adjarabet. The design of Aviator logo was initially used for the land casino Aviator. At the same time, Adjarabet, which was also owned by Ugulava, launched the crash game Aviator in collaboration with Spribe OÜ. As the creation of the game was financed by Adjarabet (while still under Termuraz Ugulava’s ownership), City Loft provided its bare consent for Adjarabet to use the same Aviator logo and airplane image.
Gogilidze says that Aviator crash game was launched on the Adjarabet online casino in January 2019, when the company was still 100% owned by Teimuraz Ugulava. Soon after launching the game, Adjarabet was sold to Flutter Entertainment Plc. None of the agreements executed with Flutter provided any rights to the Aviator trademarks. Moreover, the Agreement provided the list of trademarks transferred to the purchaser as a result of the share sale, which included the brand “Adjarabet”, also registered in the State Trademark Agency back at the time, but not the trademark “Aviator.”
Spribe OÜ and Adjarabet continued using the logo for the game on the Adjarabet platform in both the Georgian and Armenian markets until January 2024.
Gogilidze says that when Spribe OÜ decided to take the game outside Georgia, it deliberately made a slight modification to the logo and continued to use modified logo outside. At the same time, Spribe OÜ applied for registration of the modified logo in Georgia in 2022 and in the European Union in 2023.
As detailed in the court submissions, in 2022 all intellectual property related to the Aviator trademark and the airplane image was transferred from City Loft to Aviator LLC, a gaming company active in the land casino sector in Georgia. In order to protect its IP rights, Aviator LLC brought the invalidation action before the Georgian courts against, amongst others, Spribe OÜ.
For further information and media queries, please contact Aviator LLC’s representatives at info.aviator@mikadze.ge.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904224604/en/
Contacts
Nikoloz Gogilidze, info.aviator@mikadze.ge
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom